Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT07852988

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07852988
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07852988. Randomized; double masking; primary purpose treatment. Start 2026-08-01 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pancreatin Added to Standard Antihyperglycemic Therapy in Patients With Type 2 Diabetes
Condition
Type 2 Diabetes (T2DM)
Intervention (Drug)
Pancreatin
Intervention (Drug)
Placebo
Lead sponsor
Silesian Centre for Heart Diseases (class: other)
Collaborator
Medical University of Silesia (class: other)

Record details

Record id
cardio:ct-nct07852988
Content hash
6db12288125c41f0db23f65de99af9ee10d8f82bce0138e4e0009ab719812338